LY-3200882 | B2350

LY-3200882 is a potent and ATP-competitive inhibitor of TGF-β receptor type 1 (TGF-βRI). It inhibits TGF-β-induced SMAD phosphorylation in vitro and in vivo and exhibits antitumor activity in the 4T1-LP triple negative breast cancer orthotopic tumor model.

LY-3200882 is a potent and ATP-competitive inhibitor of TGF-β receptor type 1 (TGF-βRI). It inhibits TGF-β-induced SMAD phosphorylation in vitro and in vivo and exhibits antitumor activity in the 4T1-LP triple negative breast cancer orthotopic tumor model.

B2350 | LY-3200882 DataSheet

Alternate Name/Synonyms: 4-[[4-[[1-cyclopropyl-3-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl]oxy]-2-pyridinyl]amino]-α,α-dimethyl-2-pyridinemethanol

Appearance: Crystalline solid

Formulation:

CAS Number: 1898283-02-7

Structure Available?: Yes

Peptide sequence: N/A

Salt Form: N/A

Molecular Formula: C₂₄H₂₉N₅O₃

Molecular Weight: 435.53

Cell-Permeable?: TRUE

Purity: ≥98% by HPLC

Solubilities: >50 mg/ml (DMSO) in 0

Handling: Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of exposure.

Country of Origin: USA

Tag Line: A TGF-β receptor type 1 (TGF-βRI) inhibitor

MDL Number:

PubChem CID: 121249291

SMILES: CC(C)(C1=NC=CC(=C1)NC2=NC=CC(=C2)OC3=CN(N=C3C4CCOCC4)C5CC5)O

InChi: InChI=1S/C24H29N5O3/c1-24(2,30)21-13-17(5-9-25-21)27-22-14-19(6-10-26-22)32-20-15-29(18-3-4-18)28-23(20)16-7-11-31-12-8-16/h5-6,9-10,13-16,18,30H,3-4,7-8,11-12H2,1-2H3,(H,25,26,27)

InChi Key: PNPFMWIDAKQFPY-UHFFFAOYSA-N